Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 2012

View Archived Issues

Chaperone Therapeutics receives grant for Parkinson's research

Estrogen receptor PET imaging improves diagnostic understanding of patients with breast cancer

VT-464 reduces tumor growth in prostate cancer model

ARN-509 is well tolerated in phase I/II study

Novel lysophospholipid S1P1 receptor agonists disclosed by Merck Serono

Affibody and Creative Antibiotics to collaborate on targeted antibiotics

Recruitment begins in phase I SGT-94 gene therapy study

Agennix halts phase II/III talactoferrin trial in severe sepsis

Scientists at Allergan prepare new prostanoid receptor antagonists

U.S. study uncovers new therapeutic target for breast cancer

Novel antiviral agents disclosed by Gilead Sciences

D-Pharm receives recommendation to stop recruitment in MACSI stroke study

Intercell reports on two phase III studies of Ixiaro/Jespect

Reviva Pharmaceuticals synthesizes new monoamine transporter inhibitors

Researchers at Ironwood Pharmaceuticals patent novel GCS activators

FDA approves Janumet XR for type 2 diabetes

Compugen reports data on therapeutic potential of CGEN-15001T

Study investigates cause of FSHD and identifies candidate FSHD biomarkers

Japanese company synthesizes new neutrophil elastase inhibitors

Dynavax reports on Heplisav pre-BLA meeting with FDA

StemCells receives FDA clearance to conduct study in macular degeneration

Nuvo Research launches Synera in U.S.

Japanese approval for new formulation of Fosrenol

Critical Outcome Technologies readies oral formulation candidates for phase I cancer study

Inhibition of iron accumulation in brain can prevent neurodegenerative disorders

Threshold Pharmaceuticals and Merck KGaA enter global agreement for hypoxia-targeted TH-302

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...